Abstract:To explore the auxiliary value of combining CT features with existing response evaluation criteria in the prediction of progressive disease (PD) in gastrointestinal stromal tumors (GIST) patients treated with sunitinib. Eighty-one patients with GISTs who received sunitinib were included in this retrospective multicenter study and divided into training and external validation cohorts. Progression at six months was determined as a reference standard. The predictive performance of the RECIST 1.1 and Choi criteria was compared. CT features at baseline and the first follow-up were analyzed. Logistic regression analyses were used to determine the most significant predictors and develop modified criteria. A total of 216 lesions showed a good response and 107 showed a poor response in 81 patients. The RECIST 1.1 criteria performed better than the Choi criteria in predicting progression (AUC, 0.75 vs. 0.69, p = 0.04). The expanded/intensified high-enhancement area, blurred tumor-tissue interface, and progressive enlarged vessels feeding or draining the mass (EVFDM) differed significantly between lesions with good and poor responses in the training cohort (p = 0.001, 0.003, and 0.000, respectively). Multivariate analysis revealed that the expanded/intensified high-enhancement area (p = 0.001), progressive EVFDM (p = 0.000), and RECIST PD (p = 0.000) were independent predictive factors. Modified RECIST (mRECIST) criteria were developed and showed significantly higher AUCs in the training and external validation cohorts than the RECIST 1.1 criteria (training: 0.81 vs. 0.73, p = 0.002; validation: 0.82 vs. 0.77, p = 0.04). The mRECIST criteria, combining CT features with the RECIST 1.1 criteria, demonstrated superior performance in the prediction of early progression in GIST patients receiving sunitinib. The mRECIST criteria, which combine CT features with the RECIST 1.1 criteria, may facilitate the early detection of progressive disease in GIST patients treated with sunitinib, thereby potentially guiding the timely switch to late-line medications or combination with surgical excision. • The RECIST 1.1 criteria outperformed the Choi criteria in identifying progression of GISTs in patients treated with sunitinib. • GISTs displayed different morphologic features on CT depending on how they responded to sunitinib. • Combining CT morphologic features with the RECIST 1.1 criteria allowed for the prompt and accurate identification of progressing GIST lesions.

Analysis on the evaluation criteria for therapeutic effect of imatinib in GIST

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Early Evaluation of Imatinib in Treatment of Gastrointestinal Stromal Tumor Using CT Imaging

Study of CT Attenuation Value in the Use of Early Evaluation of Imatinib in Treatment of Gastrointestinal Stromal Tumor

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

The strategy of surgical treatment and targeted therapy in gastrointestinal stromal tumors

Prognosis analysis of patients with intermediate and high risk gastrointestinal stromal tumor after surgery

Imaging Evaluation of Targeted Therapy for Gastrointestinal Stromal Tumor

Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

Examination Standards and Radiological Evaluation of Targeted Therapy for Gastrointestinal Stromal Tumors

Comprehensive analysis of factors that involve in survival and prognosis in patients with gastrointestinal stromal tumors

[Efficacy analysis of targeted therapy combined with surgery in the treatment of recurrent and metastatic gastrointestinal stromal tumor].

The Diagnosis and Treatment of Colorectal Gastrointestinal Stromal Tumors

Efficacy and Safety of the Imatinib in the Treatment of 73 Gastrointestinal Stromal Tumors

CT Features Combined with RECIST 1.1 Criteria Improve Progression Assessments of Sunitinib-Treated Gastrointestinal Stromal Tumors.

Targeted Therapy and Its Application on Gastrointestinal Stromal Tumor

Diagnosis and Treatment of Gastrointestinal Stromal Tumors (GIST) :An Analysis of 87 Cases

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)